DaxorDXR
Market Cap: $44.3M
About: Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
Employees: 750
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
10% more capital invested
Capital invested by funds: $671K [Q1] → $740K (+$69.4K) [Q2]
0.29% less ownership
Funds ownership: 1.93% [Q1] → 1.64% (-0.29%) [Q2]
14% less funds holding
Funds holding: 7 [Q1] → 6 (-1) [Q2]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Ascendiant Capital Edward Woo 43% 1-year accuracy 20 / 47 met price target | 170%upside $25 | Buy Maintained | 9 Sept 2024 |
Financial journalist opinion
Based on 5 articles about DXR published over the past 30 days